C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells

Rustam Esanov, Kinsley C. Belle, Marka van Blitterswijk, Veronique V. Belzil, Rosa Rademakers, Dennis W. Dickson, Leonard Petrucelli, Kevin B. Boylan, Derek M Dykxhoorn, Joanne Wuu, Michael G Benatar, Claes R Wahlestedt, Zane R Zeier

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Among several genetic mutations known to cause amyotrophic lateral sclerosis (ALS), a hexanucleotide repeat expansion in the C9orf72 gene is the most common. In approximately 30% of C9orf72-ALS cases, 5-methylcytosine (5mC) levels within the C9orf72 promoter are increased, resulting in a modestly attenuated phenotype. The developmental timing of C9orf72 promoter hypermethylation and the reason why it occurs in only a subset of patients remain unknown. In order to model the acquisition of C9orf72 hypermethylation and examine the potential role of 5-hydroxymethylcytosine (5hmC), we generated induced pluripotent stem cells (iPSCs) from an ALS patient with C9orf72 promoter hypermethylation. Our data show that 5mC levels are reduced by reprogramming and then re-acquired upon neuronal specification, while 5hmC levels increase following reprogramming and are highest in iPSCs and motor neurons. We confirmed the presence of 5hmC within the C9orf72 promoter in post-mortem brain tissues of hypermethylated patients. These findings show that iPSCs are a valuable model system for examining epigenetic perturbations caused by the C9orf72 mutation and reveal a potential role for cytosine demethylation.

Original languageEnglish (US)
Pages (from-to)171-177
Number of pages7
JournalExperimental Neurology
Volume277
DOIs
StatePublished - Mar 1 2016

Fingerprint

Induced Pluripotent Stem Cells
Amyotrophic Lateral Sclerosis
5-Methylcytosine
Mutation
Cytosine
Motor Neurons
Epigenomics
Phenotype
Brain
Genes
5-hydroxymethylcytosine

Keywords

  • Amyotrophic lateral sclerosis
  • C9orf72
  • Cytosine hydroxymethylation
  • Repeat expansion

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. / Esanov, Rustam; Belle, Kinsley C.; van Blitterswijk, Marka; Belzil, Veronique V.; Rademakers, Rosa; Dickson, Dennis W.; Petrucelli, Leonard; Boylan, Kevin B.; Dykxhoorn, Derek M; Wuu, Joanne; Benatar, Michael G; Wahlestedt, Claes R; Zeier, Zane R.

In: Experimental Neurology, Vol. 277, 01.03.2016, p. 171-177.

Research output: Contribution to journalArticle

Esanov, Rustam ; Belle, Kinsley C. ; van Blitterswijk, Marka ; Belzil, Veronique V. ; Rademakers, Rosa ; Dickson, Dennis W. ; Petrucelli, Leonard ; Boylan, Kevin B. ; Dykxhoorn, Derek M ; Wuu, Joanne ; Benatar, Michael G ; Wahlestedt, Claes R ; Zeier, Zane R. / C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. In: Experimental Neurology. 2016 ; Vol. 277. pp. 171-177.
@article{133c2a3a482846df8370981c636db7c2,
title = "C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells",
abstract = "Among several genetic mutations known to cause amyotrophic lateral sclerosis (ALS), a hexanucleotide repeat expansion in the C9orf72 gene is the most common. In approximately 30{\%} of C9orf72-ALS cases, 5-methylcytosine (5mC) levels within the C9orf72 promoter are increased, resulting in a modestly attenuated phenotype. The developmental timing of C9orf72 promoter hypermethylation and the reason why it occurs in only a subset of patients remain unknown. In order to model the acquisition of C9orf72 hypermethylation and examine the potential role of 5-hydroxymethylcytosine (5hmC), we generated induced pluripotent stem cells (iPSCs) from an ALS patient with C9orf72 promoter hypermethylation. Our data show that 5mC levels are reduced by reprogramming and then re-acquired upon neuronal specification, while 5hmC levels increase following reprogramming and are highest in iPSCs and motor neurons. We confirmed the presence of 5hmC within the C9orf72 promoter in post-mortem brain tissues of hypermethylated patients. These findings show that iPSCs are a valuable model system for examining epigenetic perturbations caused by the C9orf72 mutation and reveal a potential role for cytosine demethylation.",
keywords = "Amyotrophic lateral sclerosis, C9orf72, Cytosine hydroxymethylation, Repeat expansion",
author = "Rustam Esanov and Belle, {Kinsley C.} and {van Blitterswijk}, Marka and Belzil, {Veronique V.} and Rosa Rademakers and Dickson, {Dennis W.} and Leonard Petrucelli and Boylan, {Kevin B.} and Dykxhoorn, {Derek M} and Joanne Wuu and Benatar, {Michael G} and Wahlestedt, {Claes R} and Zeier, {Zane R}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.expneurol.2015.12.022",
language = "English (US)",
volume = "277",
pages = "171--177",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells

AU - Esanov, Rustam

AU - Belle, Kinsley C.

AU - van Blitterswijk, Marka

AU - Belzil, Veronique V.

AU - Rademakers, Rosa

AU - Dickson, Dennis W.

AU - Petrucelli, Leonard

AU - Boylan, Kevin B.

AU - Dykxhoorn, Derek M

AU - Wuu, Joanne

AU - Benatar, Michael G

AU - Wahlestedt, Claes R

AU - Zeier, Zane R

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Among several genetic mutations known to cause amyotrophic lateral sclerosis (ALS), a hexanucleotide repeat expansion in the C9orf72 gene is the most common. In approximately 30% of C9orf72-ALS cases, 5-methylcytosine (5mC) levels within the C9orf72 promoter are increased, resulting in a modestly attenuated phenotype. The developmental timing of C9orf72 promoter hypermethylation and the reason why it occurs in only a subset of patients remain unknown. In order to model the acquisition of C9orf72 hypermethylation and examine the potential role of 5-hydroxymethylcytosine (5hmC), we generated induced pluripotent stem cells (iPSCs) from an ALS patient with C9orf72 promoter hypermethylation. Our data show that 5mC levels are reduced by reprogramming and then re-acquired upon neuronal specification, while 5hmC levels increase following reprogramming and are highest in iPSCs and motor neurons. We confirmed the presence of 5hmC within the C9orf72 promoter in post-mortem brain tissues of hypermethylated patients. These findings show that iPSCs are a valuable model system for examining epigenetic perturbations caused by the C9orf72 mutation and reveal a potential role for cytosine demethylation.

AB - Among several genetic mutations known to cause amyotrophic lateral sclerosis (ALS), a hexanucleotide repeat expansion in the C9orf72 gene is the most common. In approximately 30% of C9orf72-ALS cases, 5-methylcytosine (5mC) levels within the C9orf72 promoter are increased, resulting in a modestly attenuated phenotype. The developmental timing of C9orf72 promoter hypermethylation and the reason why it occurs in only a subset of patients remain unknown. In order to model the acquisition of C9orf72 hypermethylation and examine the potential role of 5-hydroxymethylcytosine (5hmC), we generated induced pluripotent stem cells (iPSCs) from an ALS patient with C9orf72 promoter hypermethylation. Our data show that 5mC levels are reduced by reprogramming and then re-acquired upon neuronal specification, while 5hmC levels increase following reprogramming and are highest in iPSCs and motor neurons. We confirmed the presence of 5hmC within the C9orf72 promoter in post-mortem brain tissues of hypermethylated patients. These findings show that iPSCs are a valuable model system for examining epigenetic perturbations caused by the C9orf72 mutation and reveal a potential role for cytosine demethylation.

KW - Amyotrophic lateral sclerosis

KW - C9orf72

KW - Cytosine hydroxymethylation

KW - Repeat expansion

UR - http://www.scopus.com/inward/record.url?scp=84953889368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953889368&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2015.12.022

DO - 10.1016/j.expneurol.2015.12.022

M3 - Article

C2 - 26746986

AN - SCOPUS:84953889368

VL - 277

SP - 171

EP - 177

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -